Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) saw unusually large options trading on Thursday. Investors bought 10,013 call options on the company. This is an increase of approximately 10,784% compared to the average daily volume of 92 call options.
Wall Street Analyst Weigh In
A number of brokerages recently commented on GALT. StockNews.com raised Galectin Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, April 1st. HC Wainwright reiterated a "buy" rating and issued a $11.00 price objective on shares of Galectin Therapeutics in a report on Tuesday.
Check Out Our Latest Stock Report on Galectin Therapeutics
Galectin Therapeutics Trading Up 9.9 %
GALT traded up $0.38 during trading on Thursday, reaching $4.20. The stock had a trading volume of 403,840 shares, compared to its average volume of 115,270. The stock's 50 day moving average is $2.22 and its two-hundred day moving average is $2.00. The company has a market capitalization of $259.98 million, a price-to-earnings ratio of -5.68 and a beta of 0.84. Galectin Therapeutics has a one year low of $1.28 and a one year high of $4.21.
Hedge Funds Weigh In On Galectin Therapeutics
A number of institutional investors have recently added to or reduced their stakes in GALT. Retirement Guys Formula LLC increased its holdings in shares of Galectin Therapeutics by 87.0% during the fourth quarter. Retirement Guys Formula LLC now owns 21,500 shares of the company's stock valued at $36,000 after acquiring an additional 10,000 shares in the last quarter. AE Wealth Management LLC raised its position in Galectin Therapeutics by 72.7% in the 3rd quarter. AE Wealth Management LLC now owns 26,841 shares of the company's stock worth $52,000 after buying an additional 11,300 shares during the last quarter. Beacon Capital Management LLC raised its position in Galectin Therapeutics by 89.6% in the 4th quarter. Beacon Capital Management LLC now owns 23,905 shares of the company's stock worth $40,000 after buying an additional 11,300 shares during the last quarter. Traynor Capital Management Inc. purchased a new position in Galectin Therapeutics in the 3rd quarter worth about $67,000. Finally, D.A. Davidson & CO. raised its position in Galectin Therapeutics by 15.2% in the 3rd quarter. D.A. Davidson & CO. now owns 37,825 shares of the company's stock worth $73,000 after buying an additional 5,000 shares during the last quarter. Institutional investors own 11.68% of the company's stock.
About Galectin Therapeutics
(
Get Free Report)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
Further Reading
Before you consider Galectin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galectin Therapeutics wasn't on the list.
While Galectin Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
